Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAV132 and Moxifloxacin in Healthy Volunteers
NCT02176005Phase 1Completed
- Sponsor
- Da Volterra
- Start
- Mar 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DAV132 in Clostridioides difficile infection (CDI) and dysbiosis (4 arms), sponsored by Da Volterra. Primary endpoint: Area Under the Free Moxifloxacin Fecal Concentration-time Curve (AUC D1-D16). Started Mar 2014; status: completed.
02
Drugs
DAV132
03
Conditions
Clostridioides difficile infection (CDI)dysbiosis
Beyond the preview
Go deeper on NCT02176005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02176005.